{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-026002","form_type":"8-K","ticker":"QCLS","cik":"0001321834","company_name":"Q/C TECHNOLOGIES, INC.","filed_at":"2023-07-31T23:59:59+00:00","discovered_at":"2026-05-14T18:03:33.562047+00:00","generated_at":"2026-06-12T21:50:12.584136+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"MyMD announces positive Phase 2 topline results for MYMD-1 in sarcopenia/frailty","bullets":["Study met primary endpoints: significantly reduced TNF-α (P=0.008), sTNFR1 (P=0.02), and IL-6 (P=0.03) levels.","All pharmacokinetic and secondary safety/tolerability endpoints achieved; no treatment-related adverse events.","Company to present data to FDA and intends to advance MYMD-1 into Phase 3 for sarcopenia.","MYMD-1 is first oral TNF-α inhibitor candidate; potential first FDA-approved drug for sarcopenia if approved."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-026002","json":"https://secwatch.observer/filing/0001493152-23-026002.json","markdown":"https://secwatch.observer/filing/0001493152-23-026002.md","text":"https://secwatch.observer/filing/0001493152-23-026002.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1321834/000149315223026002/0001493152-23-026002-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1321834/000149315223026002/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T21:50:12.584136+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}